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rand their physician members can reflect on their roles and
responsibilities in this area and contribute to policies which
are in the best interests of patients, providers and society. It
is hoped that this will help to resolve the differences
between physicians on this topic.
This document wilt be reviewed regularly and revised as
times and thinking change.
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Objective. To evaluate the efficacy and safety of Repotin,
a locally produced recombinant human erythropoietin
(rHuEPO), in the treatment of the anaemia of chronic renal
failure (ACRF).
Design. The study consisted of two multicentre non-
randomised open stages.
Setting. Renal units at several teaching hospitals in
South Africa.
Participants. Haemodialysis patients with haemoglobin
(Hb) levels less than 8.0 g/dl were recruited. The first stage
examined 26 patients during a 12-week period in which
the dose of intravenous rHuEPO was adjusted according
to haematological response. In the second stage 27
patients were stabilised with intravenous rHuEPO and then
Department of Medicine, University of Cape Town, and Renal Unit,
Groote Schuur Hospital, Cape Town
C. R. Swanepoel FAC.P (EOIN.l
Department of Internal Medicine, University of Stellenbosch, and
Renal Unit, Tygerberg Hospital, Tygerberg, W. Cape
M. R. Moosa. FCP (SA)
Division of Nephrology, Department of Medicine, University of the
Witwatersrand, Johannesburg
A. M. Meyers FC P ISAJ
Renal Unit, Universitas Hospital, 810emfontein
B. P. Botha. M_MED
Department of Pharmacology, University of Cape Town
A. J. Smart. 6 PHARM
R. Goodman 6 se HONS lOPll
Division of Biometry, FARMOVS Research Centre, University of the
Orange Free State, Bloemfontein
R. Schall. PH.D.
Bioclones (pty) Ltd, Sandton, Gauteng
G. F. Rowland PHD.
H. J. Keogh. 0 se
E. H. Merrifield PH 0
1266 \'olUnlt' 86 No. /0 Ortober /996 SAMJ
maintained at a Hb level above 8.0 gldl by subcutaneous
administration for up to 1 year.
Outcome measures. In both stages, outcome was
measured by clinical examination, blood pressure, full
haematological parameters and blood chemistry.
Results. In stage 1, all patients responded to therapy with
a statistically significant increase in Hb from geometric
means of 6.28 g/dl to 8.50 g/dl (geometric SOs of 1.17 and
1.20 respectively). The doses used ranged from 25 IU to
125lU/kg {average 47.1}.ln the second stage, Hb levels
reached a mean of 8.06 g/dl (SO 0.9) and were maintained
at target range with an average dose of 55.5 IU/kg three
times a week. Apart from changes in serum iron, ferritin
(associated with increased haematopoiesis) and potassium,
there were no significant aJterations in blood chemistry. The
incidence of adverse events reported during the 12-month
second stage was no greater than that reported for other
fonns of rHuEPO therapy.
Conclusion. Repotin is a safe and effective rHuEPO
preparation for the treatment of ACRF.
S Afr Mad J 1996: 86: 1266-1269.
A relative deficiency of erythropoietin is the most important
factor contributing to the anaemia of chronic renal failure
(ACRF)' Recombinant DNA technology has led to the
production of erythropoietin which, with its use, has
revolutionised the management of this anaemia.2 Repotin is
a version of recombinant human erythropoietin (rHuEPO)
that is produced in South Africa from a cell line derived from
baby hamster kidney (BHK) cells' Other versions of rHuEPO
in use world-wide for the treatment of ACRF are based on
the Chinese hamster ovary (CHO) celts.~'" The two versions,
although structurally identical in their amino acid sequence,
show subtle differences in the fine detail of the carbohydrate
chainse which could influence the biological activity of the
hormone.
This paper describes the clinical use of Repotin for ACRF
in South Africa, pertormed in two stages. The first objective
was to demonstrate the efficacy and safety of Repotin in
overcoming ACRF and was designed to establish a Repotin
dosage regimen (1 st stage). The second objective was
designed mainly to demonstrate long-term safety of Repotin
use for ACRF patients stabilised on a maintenance dose
(2nd stage). The overall aim was to determine whether,
despite minor structural differences between Repotin and
the CHQ-derived rHuEPO, the efficacy and adverse events
profiles were similar to those described by others. 7.i
Materials and methods
First stage
The first stage was a non-randomised, open, multicentre,
single-group study of efficacy, dosage determination and
safety of Repotin in ACRF patients on regular haemodialysis
over a 12-week period. Criteria for inclusion were that
patients had to be in a stable condition without a history of
admission to hospital due to decompensation for 60 days
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prior to trial inclusion. Subjects of either sex aged between
20 and 60 years, undergoing haemodialysis three times
weekly and with a haemoglobin level of less than 8 gldl,
were eligible for inclusion. Subjects were required to have
stable vascular access and women had to be non-pregnant
with negative pregnancy tests. All subjects gave informed
consent prior to inclusion. Exclusion criteria included
anaemia due to factors other than chronic renal failure,
uncontrolled hypertension, insulin-dependent diabetes,
hepatic dysfunction, prior treatment with androgens or other
rHuEPO preparations, and known hypersensitivity to human
serum albumin and/or mammalian cell-derived products.
Patients contemplating elective surgery during the course of
the study, or those who had received a blood transfusion
within 60 days of trial commencement, were also excluded.
Patients complying with the inclusion criteria entered the
study and received Repotin at an initial dosage of 25 IU/kg
body weight, 3 times per week post-dialysis over 1 minute
by intravenous injection via the dialysis tubing. If the
haemoglobin (Hb) level failed to increase by 0.5 g/dl in the
first 2 weeks or by 1.0 gldl in the first 4 weeks of therapy,
the dosage was increased by 25 IU/kg three times a week
until the Hb level increased by more than 1.4 gldl in any 2-
week period or until the Hb reached the range of 9.0 - 10.0
g/dl (target range). If the Hb reached or exceeded 10.0 g/dl,
Repotin was withheld until the Hb fell below 10.0 g/dl
whereupon the Repotin was recommenced at a dose
lowered by 25 IU/kg three times a week.
Systolic and diastolic blood pressures (supine), oral
temperature and pulse were recorded before and 10 minutes
after every administration of Repotin. A full blood count and
differential blood count were performed on each patient at
baseline and twice weekly throughout the stUdy period. A
full blood chemistry profile was assessed at baseline and at
2-weekly intervals throughout the study.
Second stage
This was a non-randomised, open multicentre study to
document the utilisation of Repotin and the resulting medical
consequences over a 12-month period, in stable patients
undergoing hamodialysis. Inclusion and exclusion criteria
were the same as for the first stage. The dosage regimen
followed to achieve target Hb levels was the same as in the
first stage (stabilisation phase). When the target Hb range of
9.0 - 10.0 g/dl was achieved, each patient entered an
individualised maintenance regimen in which administration
was changed from an intravenous to a subcutaneous route.
This regimen was designed to keep Hb levels in the target
range of 9.0 - 10.0 g/dl. If it fell below the target range and
the serum ferritin level was at least 100 nglml, the Repotin
dose was increased by 25 IU/kg three times a week. Dose
increases were restricted to no more than one per month.
When Hb levels exceeded 10.0 gldl, Repotin therapy was
temporarily discontinued as in the first stage.
Systolic and diastolic blood pressures (supine), oral
temperature and pulse were recorded before and 10 minutes
after every administration of Repotin until the target Hb was
reached. Thereafter these measurements were done
fortnightly.
A full blood count (and differential count), as well as a full
blood chemistry profile, were assessed at baseline and
weekly until the target Hb level was achieved. Thereafter
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these investigations were undertaken monthly. If there were
dosage changes, weekly Hb measurements were carried out
for 6 weeks.
Statistical methods
The change in the haematological variables from baseline to
end-point (week 12) was analysed by calculation of point
estimates and 95% confidence intervals for the 'week
12/baseline' mean ratio of the variable in question. The
confidence intervals were obtained by calculation of a
conventional paired t-test-based confidence interval for the
'week 12/baseline' on the logarithmic scale, and then taking
the antilog of the confidence limits.
The point estimate for the 'week 12/baseline' ratio was
obtained as the geometric mean of the individual ratios of
the week 12 and baseline data, respectively.
Results
First stage
Thirty-four patients were enrolled at this stage. Eight
patients were withdrawn: 1 patient was a protocol violator,
who should have been excluded due to iron deficiency; 3
patients were lost to follow-up; 1 died; 1 developed
dizziness; and 2 required blood transfusions (1 following
surgery and the other following extensive burn wounds).
Thus 26 patients - 15 males and 11 females, mean ages
41.1 (range 1g - 60) and 39.3 (range 23 - 56) years
respectively - were included in the main efficacy analysis
and 31 patients who received study treatment were included
in the safety analysis. Apart from the events mentioned
above, no patient was withdrawn because of the adverse
effects of treatment. Dose levels used throughout this stage
all commenced at 25 IUlkg three times a week and were
increased according to the schedule where necessary. The
maximum dose needed was 125 IUlkg three times a week
and the average throughout the stage was 47.1 IU/kg three
times a week.
Twenty-five of the 26 patients' Hb levels at endpoint were
not lower than at baseline and for 15 patients the target level
of g.O g/dl was reached during the study period. Table I
shows some important features of the efficacy analysis.
Haemoglobin, the primary efficacy variable, and haematocrit
increased significantty during the 12-week period and the
serum ferritin level fell. White cell and platelet counts were
not significantly affected. Other haematological variables
that increased significantly were red blood cells, monocytes
and reticulocytes. Significant increases were observed in
total iron-binding capacity and iron levels. These changes
should be seen in the light of the fact that supplementary
iron was taken by all subjects included in the main efficacy
analysis.
Second stage
Twenty-seven subjects (17 male, 10 female) were
successfully enrolled and followed up during the course of
the study for up to 12 months. Twenty-three were initially
started on a regimen to improve Hb levels up to 9.0 g/dl
(stabilisation phase); the remaining 4 in whom a Hb level of
Table I. The effect of Repotin treatment on haematologieal and
blood chemistry parameters (Geometric means (and geometric
standard deviations) on values from 26 subjects)
After Mean 95% Cl
Baseline 12 weeks ratio (%)T (%)'
Haemoglobin 6.28(1.17) 8.50 (1.20) 135 124 - 147"
(gldl)
Haematocrit 18.6 (1.21) 26.2 (1.19) 141 129 - 153'
(%)
White cells 5.30 (1.31) 5.93 (1.42) 112 100 - 125
(x 10'A)
Platelets 201 (1.51) 230 (1.45) 114 102 - 128
(x 10'/1)
Red blood cells 2.20 (1.19) 3.00 (1.18) 136 126 - 148·
(x 10"/1)
Monocytes 0.27 (2.06) 0.41 (1.54) 155 126 - 192'
(x 10'/1)
Reticulocytes 19.8 (3.19) 47.3 (2.57) 239 177-323'
(x 10'A)
Iron ijJmoVQ 11.0 (2.57) 16.9 (2.15) 153 102 - 230'
Ferritin ~gII) 148 (3.80) 86.0 (3.33) 58 41.4-81.2
Total iron-binding 42.4 (1.18) 49.9 (1.14) 118 107 - 130'
capacity ~moV1)
• A statistically significant increase.
t Geometric mean of individual week 12/baseline ratios.
t 95% conventional confidence interval for- the mean ratio.
1l A statistically significant decrease.
9.0 g/dl had been reached were enrolled directly into a
maintenance phase. Fourteen subjects were entered and
monitored by the Renal Unit, Department of Medicine,
University of Cape Town, and the remainder by the
corresponding unit, University of Stellenbosch. As in the first
stage, dosage was adjusted according to Hb response with
the overall average doses being 63.4 IU/kg three times a
week (range 25 - 100) during stabilisation and 55.5 IU/kg
three times a week during the maintenance phase. The main
haematological efficacy variables showed the same
response during stabilisation as in the first study with a
statistically significant rise in both Hb and haematocrit from
week 6 of therapy. By week 12, the Hb had reached a mean
of 8.06 g/dl (SO 0.93). This significant rise was maintained
throughout therapy, aI1hough a slight dip in mean Hb levels
was evident dUring months 3 and 7 of the maintenance
period due to concomitant systemic infections in 2 patients
and/or a reduction in Repotin dose.
This second stage enabled the safety of Repotin to be
evaluated over 12.5 patient-years. A total of 46 adverse
events were recorded in 21 subjects receiving Repotin. Of
these, only 7 events were thought to be in any way caUsally
associated with Repotin (Table 11).
Table 11. Adverse events recorded during the second stage of
Repotin use in ACRF
Incidence per
Event No. Relationship patient-year
Ru-like symptoms 1 Possibly 0.08
Fever, lightheadedness 1 Possibly 0.08
Clotted fistula 3 Possibly 0.24
Headache 1 Probably 0.08
Pruritus 1 Probably 0.08
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Two deaths were reported during the study period, both of
which were thought to be unrelated to drug therapy
(haematemesis and bleeding duodenal ulcer). Apart from a
rise in mean potassium levels at months 6 and 9, no other
changes in blood chemistry variables were observed
throughout the stUdy period,
Discussion
This report on the clinical use of Repotin in South Africa has
shown it to be a safe and effective form of rHuEPQ in the
treatment of ACRF. Although the number of .patients treated
is small in comparison with clinical trials of similar
erythropoietins elsewhere, it appears that the product
behaves in a manner that is indistinguishable from similar
products, resulting in a specmc dose-related increase in red
cells. This is an important finding, since Repotin is produced
in culture from a different mammalian cell line (BHK) from
that of rHuEPQ preparations in current clinical use (CHQ).
This is significant because there are minor differences
between the carbohydrate structures of BHK- and CHO-
derived rHuEPO'J-ll and it has been shown that the
carbohydrate structure of a glycoprotein such as rHuEPO
can influence its stability and biological activity in vitro and
in vivo. 1...3
Of equal importance to the finding of similar efficacy is the
demonstration that administration of Repotin is not
associated with any more serious side-effects than those of
the widely used GHQ-derived products.1.8 By monitoring the
safety of patients on maintenance therapy over several
months during the second phase, we were able to evaluate
12.5 patient-years and demonstrate an incidence of adverse
events per patient-year that is comparable to that reported
for other products.1 The causal relationship between the
adverse events reported and administration of Repotin is
speculative. The most dramatic of these is the clotting of the
fistulas, but in other reported instances where this has
happened, it has generally occurred through rapid increases
in haematocrit and changes in the bleeding time;14 bleeding
times were not formally assessed in this study. The protocol
was specifically designed to ensure that the rate of rise in
both haemoglobin and haematocrit was kept slow and no
significant increases in blood pressure were observed. This
slow and gradual increase in haematocrit obtained by
careful dosing according to haematological response is a
mode of rHuEPO therapy now widely accepted. It is also
noteworthy that there were no signmcant effects on platelet
or white cell counts, reinforcing the knowledge that
erythropoietin acts specifically at the erythroid progenitor
level.'s
In keeping with the increase in erythropoiesis there was a
dramatic increase in iron demand, as illustrated by the
significant fall in serum ferritin levels. This fall occurred
despite the patients' being on oral iron supplements. It has,
however, been shown that in patients with ACRF on rHuEPQ
therapy, the absorption of iron from the gastro-intestinal
tract is insufficient to meet the demands of an activated
bone marrow. lE
The rise observed in serum potassium levels was not
unexpected in patients with chronic renal failure and
probably related to Repotin therapy in an indirect way, since
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the increase in patient well-being leads to dietary
indiscretions with the consequent increased intake of
potassium-eontaining foods.1
An important aspect of this study is the question of long-
term benefits of rHuEPO therapy in relation to cost of
haemodialysis in general. The economics of this type of
intervention have been the subject o~ several publications,11-19
which have perceived it as costly even in developed
countries. The advent of a locally produced version, which
will be available at a lower price, is therefore an important
step forward for South African health care.
This report provides evidence that this locally produced
product will be a safe and effective alternative to imported
preparations and, consequent on lower pricing, will become
available to a broader spectrum of the population.
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